US pharma giant seeks to expand footprint beyond cancer treatment as its biggest product nears patent cliff
Issues ranging from medicine approval delays to attacks on Harvard research grants knock driver of regional economy
Mebufotenin benzoate also requires a much shorter period of clinical supervision in trial
Commissioner says agency is hiring scientists as industry warns over delays
World’s biggest drugmaker clinches $1.3bn deal as it hunts for experimental treatments to boost its pipeline
Partnership gives group access to CSPC’s AI platform for discovering and optimising treatments
US pharmaceuticals group has been looking to rebuild pipeline before crucial cancer drug comes off patent
French company’s purchase of Blueprint Medicines boosts immunology pipeline
Anne Wojcicki calls for fresh bankruptcy auction of genetic testing company after Regeneron won bidding
A London-based start-up employs bioprospectors to scour the world for DNA to feed AI models building a digital tree of life
Being spliced on to Regeneron will free the genetic testing company from its fatal dependence on sporadic revenue
Danish company has had some poor results for new drugs designed to replace treatments when they go off patent
The entrepreneur’s London penthouse is filled with bitcoin-inspired artworks, trippy sculptures and dinosaur skulls. Its an insight into his interest in exploring new frontiers
Pharmaceutical group says deal will help it establish leadership in treating rare tumours
Swiss group becomes latest pharmaceutical company to promise investment in the face of potential tariffs
Alis Biosciences then plans to list and offer big investors an easy way to spread their bets
Deal is latest sign of the uptick in exits by private equity groups despite sluggish M&A activity
Acquisitions hold cure for pharma companies’ chronic patent cliff problem
Once researchers begin wondering whether their government might pull the rug from under them, the damage is done
The biotech group created a revolutionary technology but it never hit on a sustainable business
DNA sequencing specialist’s decision to list in London in 2021 was seen as a victory for the market at the time
The city’s ecosystem of universities, commerce and research is attracting investors and start-ups
BioArctic is developing a process to allow drugs to cross the layer of cells that protects the brain
Simon Kohl aims to capitalise on his experience with Nobel-recognised AlphaFold protein prediction system
Anthos Therapeutics was set up by Blackstone Life Sciences after it licensed abelacimab drug from Novartis in 2019
